Anti-Drug Antibody Assays

Anti-drug antibody (ADA) assays play a crucial role in the field of pharmacology and immunology. These assays are designed to detect the presence of antibodies generated by the immune system in response to a therapeutic drug. The development of ADA against biotherapeutic drugs, such as monoclonal antibodies, recombinant proteins, and gene therapy vectors, can impact drug efficacy, safety, and overall patient outcomes. Therefore, accurate and sensitive ADA assays are essential for evaluating the immunogenicity of biotherapeutic products during preclinical and clinical development phases.

Related Products

    076-20-Adalimumab-Free-Anti-drug-ELISA-IDKmonitor

    Adalimumab Free Anti-drug Antibody ELISA (IDKmonitor®)

    Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

    076-20-Adalimumab-Total-Anti-drug-ELISA-IDKmonitor

    Adalimumab Total Anti-drug Antibody ELISA (IDKmonitor®)

    Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

    076-20-Etanercept-Free-Anti-drug-Antibody-ELISA-IDKmonitor

    Etanercept Free Anti-drug Antibody ELISA (IDKmonitor®)

    IDKmonitor Etanercept Free Anti-drug Antibody ELISA is a quantitative assay that detects human antibodies against etanercept in EDTA plasma and serum samples. Etanercept is a human therapeutic monoclonal antibody used to monitor treatment for chronic rheumatic diseases such as rheumatoid arthritis.

    076-20-Golimumab-Free-Anti-drug-ELISA-IDKmonitor

    Golimumab Free Anti-drug Antibody ELISA (IDKmonitor®)

    Golimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

    076-20-Infliximab-Free-Anti-drug-ELISA-IDKmonitor

    Infliximab Free Anti-drug Antibody ELISA (IDKmonitor®)

    Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation which is a major cause of loss of drug response.

    076-20-Infliximab-Total-Anti-drug-ELISA-IDKmonitor

    Infliximab Total Anti-drug Antibody ELISA (IDKmonitor®)

    Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

    Ustekinumab-Free-Anti-drug-Antibody-ELISA-IDKmonitor logo

    Ustekinumab Free Anti-drug Antibody ELISA (IDKmonitor®)

    Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This assay enables the reliable determination of free, unbound anti-drug antibodies.

    Ustekinumab Total Anti-drug Antibody logo

    Ustekinumab Total Anti-drug Antibody ELISA (IDKmonitor®)

    Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This drug-tolerant assay enables the reliable determination of anti-drug antibodies even in the presence of ustekinumab.

    076-20-Vedolizumab-Free-Anti-drug-ELISA-IDKmonitor

    Vedolizumab Free Anti-drug Antibody ELISA (IDKmonitor®)

    The IDKmonitor Vedolizumab Free Anti-drug ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free anti-vedolizumab antibodies in plasma or serum samples. Detecting high levels of free anti-vedolizumab antibodies in patients when the drug level is low (undetectable or sub-therapeutic) may indicate poorer long-term outcomes and suggest the need to switch treatment.